You've submitted your Investigational New Drug (IND) to the FDA, you've developed the investigator brochure and you have identified investigational sites or a phase who is willing to conduct your phase 1 study. Of course, you've double checked with the investigators to make certain that they have eligible healthy volunteers or patients to be enrolled. [...]
